Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Current practices for QSP model assessment: an IQ consortium survey.

Autor: Chan JR; Global PKPD and Pharmacometrics, Eli Lilly and Company, Indianapolis, IN, 46285, USA. jrchan@lilly.com., Allen R; Worldwide Research, Development and Medical, Pfizer Inc. Kendall Square, Cambridge, MA, 02139, USA., Boras B; Worldwide Research, Development and Medical, Pfizer Inc.,, La Jolla, CA, 92121, USA., Cabal A; Eisai Inc., NJ, Nutley, USA., Damian V; GlaxoSmithKline, Collegeville, PA, 19426, USA., Gibbons FD; Takeda, Cambridge, MA, 02139, USA., Gulati A; Merck & Co. Inc., Rahway, NJ, USA., Hosseini I; Genentech Inc., South San Francisco, CA, 94080, USA., Kearns JD; Novartis Institutes for BioMedical Research, Cambridge, MA, 02139, USA., Saito R; Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan., Cucurull-Sanchez L; GlaxoSmithKline, Stevenage, Hertfordshire, UK., Selimkhanov J; Takeda Development Center Americas Inc., San Diego, CA, 92121, USA., Stein AM; Pharmacometrics, Novartis Institutes of BioMedical Research, Cambridge, MA, USA., Umehara K; Roche Pharmaceutical Research and Early Development, Basel, Switzerland., Wang G; Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, Abingdon, Oxfordshire, UK., Wang W; Clinical Pharmacology and Pharmacometrics, Janssen Research and Development, LLC, Spring House, PA, 19477, USA., Neves-Zaph S; Data and Data Science, Translational Disease Modeling, Sanofi, USA.

Publikováno v: Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2024 Oct; Vol. 51 (5), pp. 543-555. Date of Electronic Publication: 2022 Aug 11.

Requeening queenright honey bee colonies with queen cells in honey supers.

Autor: Holmes LA; Department of Biological Sciences, University of Lethbridge, 4401 University Drive, Lethbridge, AB T1K 3M4, Canada., Kearns JD; Department of Biological Sciences, University of Lethbridge, 4401 University Drive, Lethbridge, AB T1K 3M4, Canada., Ovinge LP; Alberta Beekeepers Commission, 11434-168 Street #102, Edmonton, AB T5M 3T9, Canada., Wolf Veiga P; National Bee Diagnostics Centre, Northwestern Polytechnic, PO Box 1118, Beaverlodge, AB T0H 0C0, Canada., Hoover SE; Department of Biological Sciences, University of Lethbridge, 4401 University Drive, Lethbridge, AB T1K 3M4, Canada.

Publikováno v: Journal of insect science (Online) [J Insect Sci] 2023 Sep 01; Vol. 23 (5).

A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab.

Autor: Kearns JD; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Wassmann P; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Olgac U; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Fichter M; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Christen B; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Rubic-Schneider T; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Koepke S; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Cochin de Billy B; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Ledieu D; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Andre C; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Hawtin S; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Fischer B; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Moretti F; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Hug C; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Bepperling A; TRD Biologics and CGT, Novartis Pharma AG, Basel CH-4056, Switzerland., Brannetti B; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Mendez-Garcia C; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Littlewood-Evans A; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Clemens A; Medical Affairs Region Europe, Novartis Pharma AG, Basel CH-4056, Switzerland., Grosskreutz CL; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Mehan P; TRD Biologics and CGT, Novartis Pharma AG, Basel CH-4056, Switzerland., Schmouder RL; Novartis Institutes for BioMedical Research, East Hanover, NJ 07960, USA., Sasseville V; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA., Brees D; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland., Karle AC; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.

Publikováno v: Science translational medicine [Sci Transl Med] 2023 Feb; Vol. 15 (681), pp. eabq5068. Date of Electronic Publication: 2023 Feb 01.

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.

Autor: Weiss A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Lorthiois E; Novartis Institutes for BioMedical Research, Basel, Switzerland., Barys L; Novartis Institutes for BioMedical Research, Basel, Switzerland., Beyer KS; Novartis Institutes for BioMedical Research, Basel, Switzerland., Bomio-Confaglia C; Novartis Institutes for BioMedical Research, Basel, Switzerland., Burks H; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Chen X; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Cui X; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., de Kanter R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Dharmarajan L; Novartis Institutes for BioMedical Research, Basel, Switzerland., Fedele C; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Gerspacher M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Guthy DA; Novartis Institutes for BioMedical Research, Basel, Switzerland., Head V; Novartis Institutes for BioMedical Research, Basel, Switzerland., Jaeger A; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Núñez EJ; Novartis Institutes for BioMedical Research, Basel, Switzerland., Kearns JD; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Leblanc C; Novartis Institutes for BioMedical Research, Basel, Switzerland., Maira SM; Novartis Institutes for BioMedical Research, Basel, Switzerland., Murphy J; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Oakman H; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Ostermann N; Novartis Institutes for BioMedical Research, Basel, Switzerland., Ottl J; Novartis Institutes for BioMedical Research, Basel, Switzerland., Rigollier P; Novartis Institutes for BioMedical Research, Basel, Switzerland., Roman D; Novartis Institutes for BioMedical Research, Basel, Switzerland., Schnell C; Novartis Institutes for BioMedical Research, Basel, Switzerland., Sedrani R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Shimizu T; National Cancer Center Hospital, Tokyo, Japan., Stringer R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Vaupel A; Novartis Institutes for BioMedical Research, Basel, Switzerland., Voshol H; Novartis Institutes for BioMedical Research, Basel, Switzerland., Wessels P; Novartis Pharma AG, Basel, Switzerland., Widmer T; Novartis Pharma AG, Basel, Switzerland., Wilcken R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Xu K; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Zecri F; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Farago AF; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Cotesta S; Novartis Institutes for BioMedical Research, Basel, Switzerland., Brachmann SM; Novartis Institutes for BioMedical Research, Basel, Switzerland.

Publikováno v: Cancer discovery [Cancer Discov] 2022 Jun 02; Vol. 12 (6), pp. 1500-1517.